Company Overview

Syros is pioneering the understanding of the non-coding regulatory region of the genome to advance a new wave of medicines that control the expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with ovarian and breast cancers. Syros is also developing a deep preclinical and discovery pipeline, including SY-5609, an oral CDK7 inhibitor, as well as programs in immuno-oncology and sickle cell disease. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

Management Team

Nancy Simonian, M.D.
President and Chief Executive Officer

Eric R. Olson, Ph.D.
Chief Scientific Officer

Gerald E. Quirk
Chief Legal and Administrative Officer

David A. Roth, M.D.
Chief Medical Officer

Jeremy P. Springhorn, Ph.D.
Chief Business Officer

Joseph J. Ferra
Chief Financial Officer

Syros Announces Presentation of New Preclinical Data on SY-1365 in Treatment-Resistant HR-Positive Breast Cancer Cell Lines at San Antonio Breast Cancer Symposium

Nov 9 2018, 4:01 PM EST

Syros to Present Initial Clinical Data from Combination Cohorts in Its Ongoing Phase 2 Trial of SY-1425 at ASH Annual Meeting

Nov 1 2018, 9:01 AM EDT

Stock Overview

<table>
<thead>
<tr>
<th>Symbol</th>
<th>SYRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange</td>
<td>Nasdaq</td>
</tr>
<tr>
<td>Market Cap</td>
<td>247.7m</td>
</tr>
<tr>
<td>Last Price</td>
<td>$7.36</td>
</tr>
<tr>
<td>52-Week Range</td>
<td>$6.2525 - $15.88</td>
</tr>
</tbody>
</table>

Investor Relations

Stern Investor Relations, Inc.
Hannah Deresiewicz
hannahd@sternir.com

Syros Pharmaceuticals, Inc.
620 Memorial Drive
Suite 300
Cambridge, MA 02139

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.